MAGEN TERESE LESAK

Allopathic & Osteopathic Physicians|Family Medicine WACO, TX NPI 1447740964

General Payments — all program years on this page

$3,012.50

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 91
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $374.26 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $374.2618

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
ABIOMED $81.751
Lilly USA, LLC $57.634
ITI, Inc. $51.152
GlaxoSmithKline, LLC. $36.082
Amgen Inc. $26.971
Boehringer Ingelheim Pharmaceuticals, Inc. $25.371
DEXCOM, INC. $23.181
Exact Sciences Corporation $19.521
Novo Nordisk AS $16.731
PFIZER INC. $14.621
Acerta Pharma LLC $14.111
Organon LLC $7.152

By program year

Program yearAmountRecords
2018 $335.955
2019 $42.713
2020 $367.825
2021 $824.6922
2022 $557.7316
2023 $509.3422
2024 $374.2618

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097790420 Novo Nordisk Inc $16.73 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105320236 AstraZeneca Pharmaceuticals LP $14.11 01/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111633184 Amgen Inc. $26.97 03/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114561727 Exact Sciences Corporation $19.52 06/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116180867 GlaxoSmithKline, LLC. $20.70 01/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116339623 GlaxoSmithKline, LLC. $15.38 07/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118014406 Boehringer Ingelheim Pharmaceuticals, Inc. $25.37 06/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131678145 PFIZER INC. $14.62 07/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135100232 Lilly USA, LLC $14.79 04/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135139040 Lilly USA, LLC $13.22 02/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135145523 Lilly USA, LLC $15.50 08/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135162165 Lilly USA, LLC $14.12 02/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136261462 Organon Llc $0.42 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136261466 Organon Llc $6.73 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142290187 ABIOMED $81.75 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143264642 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $21.94 01/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143264646 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $29.21 11/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153318100 Dexcom, Inc. $23.18 09/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.